Cite
HARVARD Citation
Capps, N. (2017). Impact of PCSK9 inhibitors Alirocumab and Evolocumab on total & LDL cholesterol in clinical practice. Atherosclerosis. pp. e13-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Capps, N. (2017). Impact of PCSK9 inhibitors Alirocumab and Evolocumab on total & LDL cholesterol in clinical practice. Atherosclerosis. pp. e13-. [Online].